Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Vyvgart Prior Auth | OpenPayer
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield of TennesseePolicy ID_CHS_51022026a_1026

    Efgartigimod Alfa-fcab (Vyvgart); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (Vyvgart Hytrulo)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_51022026a_1026 alerts

    Get alerted when Policy ID_CHS_51022026a_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation coverage for Vyvgart and Vyvgart Hytrulo in adults with generalized myasthenia gravis, and for Vyvgart Hytrulo in adults with chronic inflammatory demyelinating polyneuropathy. Coverage requires applicable clinical criteria, documentation, and prescribing by or consultation with a neurologist.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyEfgartigimod Alfa-fcab (Vyvgart); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (Vyvgart Hytrulo)
    Policy CodePolicy ID_CHS_51022026a_1026
    Change TypeNo material change
    Effective DateDecember 31, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes, medical records, or claims history supporting the covered indication, clinical criteria, and prior therapy history for initial requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    MGFA II-IVgMG clinical classification
    ≥5gMG activities-of-daily-living score

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥2 months
    CIDP disease course
    NeurologistPrescriber specialty
    Not coveredOther indications

    Covered and Noncovered Indications

    Initial therapy for generalized myasthenia gravis

    Covered for initial treatment of generalized myasthenia gravis when all of the following are met.

    Initial gMG therapy

    • Clinical severity: MGFA clinical classification is II to IV and MG-ADL total score is greater than or equal to 5.MGFA II-IV; MG-ADL >=5
    • Prior therapy or avoidance

      • Two immunosuppressive therapies: Inadequate response or intolerable adverse event to at least two immunosuppressive therapies over at least 12 months.>=2 therapies over >=12 months

        Examples include azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, and tacrolimus.

      • Immunosuppressive therapy and IVIG: Inadequate response or intolerable adverse event to at least one immunosuppressive therapy and intravenous immunoglobulin (IVIG) over at least 12 months.>=1 immunosuppressive therapy plus IVIG over >=12 months
      • Avoidance of therapy: Documented clinical reason to avoid therapy with immunosuppressive agents and IVIG.
    • No prohibited combination: The requested medication will not be used in combination with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna.

      Examples include Imaavy, Rystiggo, Soliris, Ultomiris, and Zilbrysq.

    Initial therapy for CIDP

    Covered for initial treatment of CIDP with Vyvgart Hytrulo when all of the following are met.

    Initial CIDP therapy

    • Disease course is progressive or relapsing/remitting for 2 months or longer.>=2 months
    • Diagnostic confirmation: Diagnosis was confirmed by electrodiagnostic testing consistent with EFNS/PNS guidelines.
    • Prior therapy or avoidance

      • Prior therapy failure or intolerance: Inadequate response or intolerable adverse event to immunoglobulins, corticosteroids, or plasma exchange.

    Continuation therapy for generalized myasthenia gravis

    Covered for continuation treatment of generalized myasthenia gravis when all of the following are met.

    Continuation gMG therapy

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Positive response: The member demonstrates a positive response to therapy, such as improvement in MG-ADL score, MG Manual Muscle Test (MMT), or MG Composite.
    • No prohibited combination: The requested medication will not be used in combination with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna.

      Examples include Imaavy, Rystiggo, Soliris, Ultomiris, and Zilbrysq.

    Continuation therapy for CIDP

    Covered for continuation treatment of CIDP with Vyvgart Hytrulo when all of the following are met.

    Continuation CIDP therapy

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Positive response: The member demonstrates a positive response to therapy, such as improvement in I-RODS, INCAT disability scale, MRC Sum score, or grip strength.

    Noncovered indications

    The following indications are not medically necessary.

    Other indications: All indications other than the specified FDA-approved indications are considered experimental/investigational and not medically necessary.

    Coverage is limited to the specified FDA-approved uses. Vyvgart is covered for adults with generalized myasthenia gravis (gMG), and Vyvgart Hytrulo is covered for adults with gMG or chronic inflammatory demyelinating polyneuropathy (CIDP). Indications outside these uses are excluded as experimental/investigational and not medically necessary.

    The requested medication must not be used in combination with another neonatal Fc receptor blocker, a complement inhibitor, or Uplizna. Examples include Imaavy or Rystiggo; Soliris, Ultomiris, or Zilbrysq; and Uplizna, respectively.

    All other indications not listed as covered FDA-approved uses are considered experimental/investigational and not medically necessary.

    Clinical Thresholds and Dosing Parameters

    MGFA Clinical Classification
    Required classificationMGFA clinical classification II to IV
    Applicable conditionGeneralized myasthenia gravis (gMG)
    Authorization period12 months
    MG-ADL Total Score
    Required scoreMG-ADL total score greater than or equal to 5
    Applicable conditionGeneralized myasthenia gravis (gMG)
    Authorization period12 months

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required. For an initial request, submit documentation supporting the applicable indication and all coverage criteria. Authorization may be granted for 12 months when the initial requirements are met.

    • Use the gMG criteria for Vyvgart or Vyvgart Hytrulo.
    • Use the CIDP criteria only for Vyvgart Hytrulo.
    • Submit the required clinical documentation with the initial request.
    Prior Authorization

    Continuation Prior Authorization

    Continuation prior authorization is required every 12 months. Reauthorization requests must document a positive clinical response and continued appropriateness of therapy, with no unacceptable toxicity or disease progression.

    • For gMG, document improvement in MG-ADL, MG Manual Muscle Test (MMT), or MG Composite, as applicable.
    • For CIDP, document improvement in I-RODS, INCAT disability scale, MRC Sum score, or grip strength, as applicable.

    Policy and Product Background

    Vyvgart is FDA-approved for the treatment of adults with generalized myasthenia gravis (gMG). Vyvgart Hytrulo is FDA-approved for adults with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP).

    Clinical Definitions

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease courseProgressive or relapsing/remitting
    DurationAt least 2 months
    ConfirmationConfirmed by electrodiagnostic testing consistent with EFNS/PNS guidelines

    Initial Treatment Requirements

    gMG initial therapy

    Initial treatment with Vyvgart or Vyvgart Hytrulo for generalized myasthenia gravis requires all of the following.

    • Prior therapy or avoidance

      • Two immunosuppressive therapies: Inadequate response or intolerable adverse event to at least two immunosuppressive therapies over at least 12 months.>=2 therapies over >=12 months

        Examples include azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, and tacrolimus.

      • Immunosuppressive therapy and IVIG: Inadequate response or intolerable adverse event to at least one immunosuppressive therapy and IVIG over at least 12 months.>=1 immunosuppressive therapy plus IVIG over >=12 months

    Continuation Treatment Requirements

    gMG continuation

    Continuation of Vyvgart or Vyvgart Hytrulo for generalized myasthenia gravis requires all of the following.

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Positive response: The member demonstrates a positive response to therapy, such as improvement in MG-ADL score, MG Manual Muscle Test (MMT), or MG Composite.
    • No prohibited combination: The requested medication will not be used in combination with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna.

      Examples include Imaavy, Rystiggo, Soliris, Ultomiris, and Zilbrysq.

    CIDP continuation

    Required Prior Therapies

    ConditionRequired prior therapyAlternative
    Generalized myasthenia gravis (gMG)Inadequate response or intolerable adverse event to at least two immunosuppressive therapies over at least 12 months, or to at least one immunosuppressive therapy plus IVIG over at least 12 months.Documented clinical reason to avoid therapy with immunosuppressive agents and IVIG.
    ConditionRequired prior therapyAlternative
    Chronic inflammatory demyelinating polyneuropathy (CIDP)Inadequate response or intolerable adverse event to immunoglobulins, corticosteroids, or plasma exchange.Documented clinical reason to avoid therapy with immunoglobulins, corticosteroids, or plasma exchange.

    Product Dosing and Quantity Limits

    Vyvgart (efgartigimod alfa-fcab)
    IndicationGeneralized myasthenia gravis (gMG)
    Dose10 mg/kg if weight is less than 120 kg; 1200 mg if weight is 120 kg or greater
    AdministrationIntravenous, weekly for 4 weeks
    Subsequent cyclesBased on clinical evaluation
    Vyvgart Hytrulo PFS
    IndicationGeneralized myasthenia gravis (gMG)
    Dose1000 mg/10,000 units subcutaneously

    Administration Route and Setting

    Billing Rule

    Administer Vyvgart intravenously

    Administer Vyvgart by the intravenous route in an infusion center. Follow the applicable weight-based regimen: 10 mg/kg weekly for 4 weeks for members weighing less than 120 kg, or 1200 mg weekly for 4 weeks for members weighing 120 kg or more.

    • Administer subsequent treatment cycles based on clinical evaluation.
    Billing Rule

    Administer Vyvgart Hytrulo subcutaneously

    Administer Vyvgart Hytrulo PFS or vial by the subcutaneous route in an office. For gMG, administer weekly for 4 weeks, with subsequent treatment cycles based on clinical evaluation.

    • PFS: 1000 mg/10,000 units subcutaneously weekly for 4 weeks for gMG.
    • Vial: 1008 mg/11,200 units subcutaneously weekly for 4 weeks for gMG.
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyEfgartigimod Alfa-fcab (Vyvgart); Efgartigimod Alfa-fcab and Hyaluronidase-qvfc (Vyvgart Hytrulo)
    Policy CodePolicy ID_CHS_51022026a_1026
    Change TypeNo material change
    Effective DateDecember 31, 2026
    Next Review DateN/A
    Key ActionSubmit chart notes, medical records, or claims history supporting the covered indication, clinical criteria, and prior therapy history for initial requests.
    SourceLink
    On This Page
    Covered and Noncovered IndicationsClinical Thresholds and Dosing ParametersAuthorization, Documentation, and Denial RisksPolicy and Product BackgroundClinical DefinitionsInitial Treatment RequirementsContinuation Treatment RequirementsRequired Prior TherapiesProduct Dosing and Quantity LimitsAdministration Route and Setting
    Avoidance of prior therapy:
    Documented clinical reason to avoid therapy with immunoglobulins, corticosteroids, or plasma exchange.
    gMG Prior Immunosuppressive Therapy
    Required durationAt least 12 months
    Two-therapy pathwayInadequate response or intolerable adverse event to at least two immunosuppressive therapies
    Alternative pathwayInadequate response or intolerable adverse event to at least one immunosuppressive therapy and IVIG over at least 12 months
    CIDP Disease Course
    Required disease courseProgressive or relapsing/remitting
    Minimum duration2 months or longer
    Diagnostic confirmationElectrodiagnostic testing consistent with EFNS/PNS guidelines
    Vyvgart Weight-Based Dose
    Weight below 120 kg10 mg/kg intravenously every week for 4 weeks
    Weight 120 kg or greater1200 mg intravenously every week for 4 weeks
    Subsequent cyclesAdminister based on clinical evaluation
  1. Document that there is no unacceptable toxicity or disease progression on the current regimen.
  2. Step Therapy

    gMG Prerequisite Therapy

    For gMG, document inadequate response or an intolerable adverse event to required prior immunosuppressive therapy, or a clinical reason to avoid immunosuppressive agents and IVIG.

    • Inadequate response or intolerance to at least two immunosuppressive therapies over at least 12 months; or
    • Inadequate response or intolerance to at least one immunosuppressive therapy and IVIG over at least 12 months; or
    • A documented clinical reason to avoid immunosuppressive agents and IVIG.
    Step Therapy

    CIDP Prerequisite Therapy

    For CIDP, document inadequate response or an intolerable adverse event to immunoglobulins, corticosteroids, or plasma exchange, or a clinical reason to avoid these therapies.

    • Applicable only to Vyvgart Hytrulo for CIDP.
    • Document the prior therapy or therapies tried and the response or adverse event.
    • If therapy is not advisable, document the clinical reason for avoidance.
    Documentation Required

    Prior Authorization Documentation

    Submit chart notes, medical records, or claims history with the initial request. Documentation must establish the applicable diagnosis, disease severity or confirmation, prior treatment history, and response or reasons therapy was avoided.

    • gMG: MGFA clinical classification and MG-ADL score.
    • gMG: Previous medications tried and response, or clinical reasons to avoid therapy.
    • CIDP: Electrodiagnostic testing, such as EMG or NCS.
    • CIDP: Previous immunoglobulins, corticosteroids, or plasma exchange and response, or clinical reasons to avoid therapy.
    • Continuation: Chart notes or medical records supporting positive clinical response.
    Note

    Neurologist Prescriber or Consultation Required

    The medication must be prescribed by or in consultation with a neurologist.

    • Document neurologist prescribing or consultation when applicable.
    Denial Risk

    Noncovered Indications

    Vyvgart is covered for adult patients with generalized myasthenia gravis. Vyvgart Hytrulo is covered for adult patients with generalized myasthenia gravis or CIDP; all other indications are considered experimental/investigational and not medically necessary.

    • Covered FDA-approved indications: adult gMG for Vyvgart or Vyvgart Hytrulo.
    • Covered FDA-approved indication: adult CIDP for Vyvgart Hytrulo only.
    • Requests for other indications may be denied as experimental/investigational and not medically necessary.
    Denial Risk

    Prohibited Combination Therapy

    Do not use the requested medication in combination with another neonatal Fc receptor blocker, a complement inhibitor, or Uplizna. This restriction applies to both initial and continuation requests.

    • Neonatal Fc receptor blockers include Imaavy and Rystiggo.
    • Complement inhibitors include Soliris, Ultomiris, and Zilbrysq.
    • Uplizna is also a prohibited combination.
    Denial Risk

    Failure to Meet Initial Criteria

    An initial request may be denied when the applicable disease-specific criteria, prerequisite treatment requirements, diagnostic documentation, or required severity thresholds are not met.

    • gMG: MGFA clinical classification must be II to IV and MG-ADL must be greater than or equal to 5.
    • gMG: Required prior immunosuppressive therapy and/or IVIG criteria must be met, unless documented clinical reasons support avoidance.
    • CIDP: Disease must be progressive or relapsing/remitting for at least 2 months.
    • CIDP: Diagnosis must be confirmed by electrodiagnostic testing consistent with EFNS/PNS guidelines.
    • CIDP: Required prior therapy or a documented clinical reason to avoid it must be established.
    Denial Risk

    Failure to Demonstrate Continuation Response

    A continuation request may be denied when the record does not demonstrate ongoing benefit, or when there is unacceptable toxicity or disease progression on the current regimen.

    • gMG: Document positive response using applicable MG-ADL, MMT, or MG Composite findings.
    • CIDP: Document positive response using applicable I-RODS, INCAT disability scale, MRC Sum score, or grip-strength findings.
    • Document absence of unacceptable toxicity and disease progression.
    Avoidance of therapy: Documented clinical reason to avoid therapy with immunosuppressive agents and IVIG.
  3. No prohibited combination: The requested medication will not be used in combination with another neonatal Fc receptor blocker, complement inhibitor, or Uplizna.

    Examples include Imaavy, Rystiggo, Soliris, Ultomiris, and Zilbrysq.

  4. CIDP initial therapy

    Initial treatment with Vyvgart Hytrulo for CIDP requires all of the following.

    • Disease course is progressive or relapsing/remitting for 2 months or longer.>=2 months
    • Diagnostic confirmation: Diagnosis was confirmed by electrodiagnostic testing consistent with EFNS/PNS guidelines.
    • Prior therapy or avoidance

      • Prior therapy failure or intolerance: Inadequate response or intolerable adverse event to immunoglobulins, corticosteroids, or plasma exchange.
      • Avoidance of prior therapy: Documented clinical reason to avoid therapy with immunoglobulins, corticosteroids, or plasma exchange.

    Continuation of Vyvgart Hytrulo for CIDP requires all of the following.

    • Safety and disease control: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Positive response: The member demonstrates a positive response to therapy, such as improvement in I-RODS, INCAT disability scale, MRC Sum score, or grip strength.
    Initial cycleEvery week for 4 weeks
    Subsequent cyclesBased on clinical evaluation
    Vyvgart Hytrulo PFS
    IndicationChronic inflammatory demyelinating polyneuropathy (CIDP)
    Dose1000 mg/10,000 units
    RouteSubcutaneous
    ScheduleEvery week
    Vyvgart Hytrulo Vial
    IndicationGeneralized myasthenia gravis (gMG)
    Dose1008 mg/11,200 units subcutaneously
    Initial cycleEvery week for 4 weeks
    Subsequent cyclesBased on clinical evaluation
    Vyvgart Hytrulo Vial
    IndicationChronic inflammatory demyelinating polyneuropathy (CIDP)
    Dose1008 mg/11,200 units
    RouteSubcutaneous
    ScheduleEvery week
  5. For CIDP, PFS is 1000 mg/10,000 units subcutaneously every week and the vial is 1008 mg/11,200 units subcutaneously every week.